Bio Path Holdings Inc (NASDAQ:BPTH)

1.20
Delayed Data
As of May 29
 -0.08 / -6.25%
Today’s Change
0.99
Today|||52-Week Range
3.62
-54.89%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$107.7M

Company Description

Bio-Path Holdings, Inc. operates as a holding company, which through its subsidiary Bio-Path, Inc. develops novel cancer therapeutic products. It is licensed for developing three lead products and nucleric acid delivery technology, including tumor targeting technology. The company's lead product candidate, Liposomal Grb-2, is a liposomal antisense drug and is in a Phase I study for blood cancers. Its second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. Bio-Path Holdings was founded by Peter Nielsen, Gabriel Lopez-Berestein and Ana Maria Tari in May 2007 and is headquartered in Houston, TX.

Contact Information

Bio-Path Holdings, Inc.
2626 South Loop
Houston Texas 77054
P:(832) 971-6616
Investor Relations:

Employees

Shareholders

Mutual fund holders6.10%
Individual stakeholders17.53%
Other institutional12.71%

Top Executives

Peter H. NielsenChairman, President, CEO, CFO, Treasurer & PAO
Ulrich W. MuellerChief Operating Officer
Ana Maria TariDirector-Preclinical Operations & Research
Tara SadeghiDirector-Clinical Operations

To view my watchlist

Not a member yet?

Sign up now for a free account